Literature DB >> 3166908

The efficacy of 5-fluorouracil in human colorectal cancer is not enhanced by thymidylate synthetase inhibition with CB3717 (N10-propargyl-5,8 dideazafolic acid).

B M Cantwell1, A L Harris.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1988        PMID： 3166908      PMCID： PMC2246772          DOI： 10.1038/bjc.1988.190

Source DB:  PubMed          Journal:  Br J Cancer        ISSN： 0007-0920            Impact factor:   7.640


× No keyword cloud information.
  10 in total

Review 1.  Chemotherapy of gastrointestinal cancer.

Authors:  C G Moertel
Journal:  N Engl J Med       Date:  1978-11-09       Impact factor: 91.245

Review 2.  Overview of current status and future direction of clinical trials with 5-fluorouracil in combination with folinic acid.

Authors:  J L Grem; D F Hoth; J M Hamilton; S A King; B Leyland-Jones
Journal:  Cancer Treat Rep       Date:  1987-12

3.  A potent antitumour quinazoline inhibitor of thymidylate synthetase: synthesis, biological properties and therapeutic results in mice.

Authors:  T R Jones; A H Calvert; A L Jackman; S J Brown; M Jones; K R Harrap
Journal:  Eur J Cancer       Date:  1981-01       Impact factor: 9.162

4.  Biochemical determinants of responsiveness to 5-fluorouracil and its derivatives in xenografts of human colorectal adenocarcinomas in mice.

Authors:  J A Houghton; S J Maroda; J O Phillips; P J Houghton
Journal:  Cancer Res       Date:  1981-01       Impact factor: 12.701

5.  A phase I evaluation of the quinazoline antifolate thymidylate synthase inhibitor, N10-propargyl-5,8-dideazafolic acid, CB3717.

Authors:  A H Calvert; D L Alison; S J Harland; B A Robinson; A L Jackman; T R Jones; D R Newell; Z H Siddik; E Wiltshaw; T J McElwain
Journal:  J Clin Oncol       Date:  1986-08       Impact factor: 44.544

6.  Patterns of cross-resistance to the antifolate drugs trimetrexate, metoprine, homofolate, and CB3717 in human lymphoma and osteosarcoma cells resistant to methotrexate.

Authors:  H Diddens; D Niethammer; R C Jackson
Journal:  Cancer Res       Date:  1983-11       Impact factor: 12.701

7.  Recent preclinical and clinical studies with the thymidylate synthase inhibitor N10-propargyl-5,8-dideazafolic acid (CB 3717).

Authors:  A H Calvert; D R Newell; A L Jackman; L A Gumbrell; E Sikora; B Grzelakowska-Sztabert; J A Bishop; I R Judson; S J Harland; K R Harrap
Journal:  NCI Monogr       Date:  1987

8.  Induction of remission in hepatocellular carcinoma with a new thymidylate synthase inhibitor, CB3717. A phase II study.

Authors:  M F Bassendine; N J Curtin; H Loose; A L Harris; O F James
Journal:  J Hepatol       Date:  1987-06       Impact factor: 25.083

9.  Phase II study of the antifolate N10-propargyl-5,8-dideazafolic acid (CB 3717) in advanced breast cancer.

Authors:  B M Cantwell; V Macaulay; A L Harris; S B Kaye; I E Smith; R A Milsted; A H Calvert
Journal:  Eur J Cancer Clin Oncol       Date:  1988-04

10.  Phase II study of the thymidylate synthetase inhibitor CB3717 (N10-propargyl-5,8-dideazafolic acid) in colorectal cancer.

Authors:  M J Harding; B M Cantwell; R A Milstead; A L Harris; S B Kaye
Journal:  Br J Cancer       Date:  1988-06       Impact factor: 7.640
  10 in total
  2 in total

Review 1.  New targets for pyrimidine antimetabolites in the treatment of solid tumours. 1: Thymidylate synthase.

Authors:  C L van der Wilt; G J Peters
Journal:  Pharm World Sci       Date:  1994-04-15

2.  Effect of 5-fluorouracil combination therapy on RNA processing in human colonic carcinoma cells.

Authors:  D A Greenhalgh; J H Parish
Journal:  Br J Cancer       Date:  1990-03       Impact factor: 7.640
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.